RepliCel Life Sciences Inc.

RepliCel Life Sciences Inc. is a British Columbia, Canada, company that is in the business of developing autologous cell therapy for certain diseases affected by cellular deficits. The diseases being addressed are pattern baldness and tendinosis. Each disease state is consistent with a deficit of a specific cell type which we believe is critical to normal function. These technologies carry issued and filed patent applications. Our technology for pattern baldness has the potential to become the world’s first autologous cellular treatment for hair loss in men and women. This cellular replication and implantation technology is designed to rejuvenate damaged, miniaturized hair follicles in balding scalp skin. Our treatment for tendinosis has the potential to be the first autologous cell treatment to heal injured tendons that have reached a chronic stage of deterioration.